Literature DB >> 19285848

Adoptive immunotherapy of cancer using CD4(+) T cells.

Pawel Muranski1, Nicholas P Restifo.   

Abstract

CD4(+) T cells are central to the function of the immune system but their role in tumor immunity remains underappreciated. It is becoming clear that there is an enormous diversity of CD4(+) T cell polarization patterns including Th1, Th2, Th17, and regulatory T cells (Tregs). These functionally divergent T cell subsets can have opposing effects -- they can trigger tumor rejection or inhibit treatment after adoptive cell transfer. Some polarized CD4(+) cells have plasticity, and their phenotypes and functions can evolve in vivo. Recent advances in understanding of polarization and differentiation of lymphocytes, as well as some intriguing developments in the clinic, indicate that the use of CD4(+) T cell subsets in the immunotherapy of cancer has unrealized potential.

Entities:  

Mesh:

Year:  2009        PMID: 19285848      PMCID: PMC2715842          DOI: 10.1016/j.coi.2009.02.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  90 in total

1.  Nomenclature for factors of the HLA system, 2004.

Authors:  S G E Marsh; E D Albert; W F Bodmer; R E Bontrop; B Dupont; H A Erlich; D E Geraghty; J A Hansen; C K Hurley; B Mach; W R Mayr; P Parham; E W Petersdorf; T Sasazuki; G M Th Schreuder; J L Strominger; A Svejgaard; P I Terasaki; J Trowsdale
Journal:  Tissue Antigens       Date:  2005-04

2.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

3.  CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Authors:  Paul A Antony; Ciriaco A Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas C Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

Review 4.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Authors:  K L Knutson; M L Disis
Journal:  Cancer Immunol Immunother       Date:  2005-01-27       Impact factor: 6.968

5.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Authors:  Marcin Kortylewski; Maciej Kujawski; Tianhong Wang; Sheng Wei; Shumin Zhang; Shari Pilon-Thomas; Guilian Niu; Heidi Kay; James Mulé; William G Kerr; Richard Jove; Drew Pardoll; Hua Yu
Journal:  Nat Med       Date:  2005-11-20       Impact factor: 53.440

6.  Primary antitumor immune response mediated by CD4+ T cells.

Authors:  Alexandre Corthay; Dag K Skovseth; Katrin U Lundin; Egil Røsjø; Hilde Omholt; Peter O Hofgaard; Guttorm Haraldsen; Bjarne Bogen
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

Review 7.  CD4+ T lymphocytes: a critical component of antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

8.  IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.

Authors:  Muneo Numasaki; Mika Watanabe; Takashi Suzuki; Hidenori Takahashi; Akira Nakamura; Florencia McAllister; Takanori Hishinuma; Junichi Goto; Michael T Lotze; Jay K Kolls; Hidetada Sasaki
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

9.  CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

Authors:  Annemieke Th den Boer; Geertje J D van Mierlo; Marieke F Fransen; Cornelis J M Melief; Rienk Offringa; René E M Toes
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

10.  Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Authors:  Karin C M Straathof; Catherine M Bollard; Uday Popat; M Helen Huls; Teresita Lopez; M Craig Morriss; Mary V Gresik; Adrian P Gee; Heidi V Russell; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2004-11-12       Impact factor: 22.113

View more
  111 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

3.  CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

Authors:  Kamel Ait-Tahar; Amanda P Liggins; Graham P Collins; Andrew Campbell; Martin Barnardo; Maite Cabes; Charles H Lawrie; Donald Moir; Chris Hatton; Alison H Banham; Karen Pulford
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

Review 4.  The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Debora Martorelli; Elena Muraro; Patrizia Comoli; Antonio Rosato
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

5.  Can antitumor immunity help to explain "oncogene addiction"?

Authors:  Nicholas P Restifo
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

Review 6.  CD4 T-cell immunotherapy for chronic viral infections and cancer.

Authors:  Alice O Kamphorst; Rafi Ahmed
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

7.  Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT.

Authors:  Sabrina H L Hoffmann; Andreas Maurer; Dorothea I Reck; Gerald Reischl; Bernd J Pichler; Manfred Kneilling; Christoph M Griessinger
Journal:  J Vis Exp       Date:  2017-04-29       Impact factor: 1.355

Review 8.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

9.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Authors:  Cyrille J Cohen; Jared J Gartner; Miryam Horovitz-Fried; Katerina Shamalov; Kasia Trebska-McGowan; Valery V Bliskovsky; Maria R Parkhurst; Chen Ankri; Todd D Prickett; Jessica S Crystal; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

10.  Autoimmunity: increasing suspects in the CD4+ T cell lineup.

Authors:  Matthew T Palmer; Casey T Weaver
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.